Karyopharm Announces Will Present Data on Selinexor at EHA Annual Meeting on Jun 11-14

Karyopharm Therapeutics Inc.

, a clinical-stage pharmaceutical company, today announced that two abstracts describing the activity of selinexor (KPT-330), the company's lead drug candidate in development for hematological malignancies and solid tumors, have been selected for presentation at the 20th Congress of the European Hematology Association (EHA) 2015 Annual Meeting taking place June 11 - 14, 2015 in Vienna, Austria. Presentations include an oral presentation describing updated survival data from an ongoing company-sponsored Phase 1b clinical trial of single-agent selinexor in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL) and a late-breaking poster describing preliminary Phase 2 results from an ongoing investigator-sponsored clinical trial of selinexor in combination with chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML). "We are excited by these promising data to be presented at EHA, which continue to demonstrate the vast potential of selinexor across hematologic malignancies," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "The long-term survival benefit demonstrated with selinexor in DLBCL and the preliminary data suggesting that selinexor can be combined with chemotherapy in relapsed/refractory AML provide further evidence of selinexor's broad and durable activity, both as a single agent and in combination therapy." The following abstracts describe the potential role of selinexor, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound in DLBCL and advanced AML. These data will be further updated in the presentations at EHA: An oral presentation with updated data from an ongoing Phase 1 clinical trial demonstrating that objective responses achieved with selinexor in this trial are durable and correlate with improved overall survival and progression free survival compared with patients who achieved stable or progressive disease, suggesting that these responses are associated with clinical benefit. Title: Patients with Heavily Pretreated Diffuse Large B-Cell Lymphoma (DLBCL) who Respond to Oral Selinexor Therapy Show Prolonged Survival: Updated Phase 1 Results Author: Kuruvilla, Princess Margaret Hospital, Toronto, Canada Abstract: S485 Session: Optimization and innovation in treating aggressive lymphomas Date/Time: Saturday, June 13, 4:45 PM - 5:00 PM A late-breaking poster presentation of preliminary data from an ongoing Phase 2 clinical trial demonstrating that selinexor in combination with standard doses of Ara-C and idarubicin is a potentially effective strategy for treating patients with AML that was relapsed or refractory after at least one line of chemotherapy, without unexpected toxicities. An overall response rate of 53% (eight) was achieved based on fifteen evaluable patients and 67% (six) of those patients went on to receive either stem cell transplant or donor lymphocyte infusion. This represents the first presentation of clinical results of selinexor in combination with chemotherapy. Title: Preliminary Phase II Results of Ara-C And Idarubicin in Combination with Selective Inhibitor of Nuclear Export (Sine) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML Author: Fiedler, Department of Internal Medicine II and Clinic (Oncology Center), University Medical Center Hamburg Abstract: LB578 Session: Acute myeloid leukemia - Clinical 4 Date/Time: Saturday, June 13, 5:15 PM - 6:45 PM